Epigenetics: Roles and Therapeutic Implications of Non-coding RNA Modifications in Human Cancers

Overview

Journal Mol Ther Nucleic Acids

Publisher Cell Press

Date 2021 Jun 30

PMID 34188972

Citations 45

Authors

Dawei Rong

Guangshun Sun

Fan Wu

Ye Cheng

Guoqiang Sun

Wei Jiang

Xiao Li

Yi Zhong

Liangliang Wu

Chuanyong Zhang

Weiwei Tang

Xuehao Wang

Affiliations

Soon will be listed here.

Abstract

As next-generation sequencing (NGS) is leaping forward, more than 160 covalent RNA modification processes have been reported, and they are widely present in every organism and overall RNA type. Many modification processes of RNA introduce a new layer to the gene regulation process, resulting in novel RNA epigenetics. The commonest RNA modification includes pseudouridine (Ψ), -methylguanosine (m7G), 5-hydroxymethylcytosine (hm5C), 5-methylcytosine (m5C), -methyladenosine (m1A), -methyladenosine (m6A), and others. In this study, we focus on non-coding RNAs (ncRNAs) to summarize the epigenetic consequences of RNA modifications, and the pathogenesis of cancer, as diagnostic markers and therapeutic targets for cancer, as well as the mechanisms affecting the immune environment of cancer. In addition, we summarize the current status of epigenetic drugs for tumor therapy based on ncRNA modifications and the progress of bioinformatics methods in elucidating RNA modifications in recent years.

Citing Articles

Identification and validation of an m5C-related lncRNA signature for predicting prognosis and immune response in clear cell renal cell carcinoma.

Ao S, Liang L, Peng L, Yang R, Chen Z, Deng T Discov Oncol. 2025; 16(1):227.

PMID: 39987537 PMC: 11847763. DOI: 10.1007/s12672-025-01987-5.

CYFIP1 coordinate with RNMT to induce osteosarcoma cuproptosis via AURKAIP1 m7G modification.

Lin Z, Wu Z, He Y, Li X, Luo W Mol Med. 2025; 31(1):74.

PMID: 39984834 PMC: 11846196. DOI: 10.1186/s10020-025-01127-3.

N7-methylguanosine modification in cancers: from mechanisms to therapeutic potential.

Wu Q, Fu X, Liu G, He X, Li Y, Ou C J Hematol Oncol. 2025; 18(1):12.

PMID: 39881381 PMC: 11780989. DOI: 10.1186/s13045-025-01665-7.

LINC02418 suppresses endometrial cancer progression via regulating miR-494-3p/RASGRF1 axis.

Li H, Bian J, Liu M, Wang Y, Shang Y, Zheng Y J Mol Histol. 2025; 56(1):72.

PMID: 39841298 DOI: 10.1007/s10735-024-10327-w.

The Role of Chronic Inflammation in Pediatric Cancer.

Mella C, Tsarouhas P, Brockwell M, Ball H Cancers (Basel). 2025; 17(1.

PMID: 39796780 PMC: 11719864. DOI: 10.3390/cancers17010154.

References

Han J, Wang J, Yang X, Yu H, Zhou R, Lu H . METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 2019; 18(1):110. PMC: 6588935. DOI: 10.1186/s12943-019-1036-9. View

Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, Ben-Haim M . The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature. 2016; 530(7591):441-6. PMC: 4842015. DOI: 10.1038/nature16998. View

Rintala-Dempsey A, Kothe U . Eukaryotic stand-alone pseudouridine synthases - RNA modifying enzymes and emerging regulators of gene expression?. RNA Biol. 2017; 14(9):1185-1196. PMC: 5699540. DOI: 10.1080/15476286.2016.1276150. View

Hamma T, Ferre-DAmare A . Pseudouridine synthases. Chem Biol. 2006; 13(11):1125-35. DOI: 10.1016/j.chembiol.2006.09.009. View

Ueda Y, Ooshio I, Fusamae Y, Kitae K, Kawaguchi M, Jingushi K . AlkB homolog 3-mediated tRNA demethylation promotes protein synthesis in cancer cells. Sci Rep. 2017; 7:42271. PMC: 5304225. DOI: 10.1038/srep42271. View

Chen X, Li A, Sun B, Yang Y, Han Y, Yuan X . 5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs. Nat Cell Biol. 2019; 21(8):978-990. DOI: 10.1038/s41556-019-0361-y. View

Wang J, Ding W, Xu Y, Tao E, Mo M, Xu W . Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1. Aging (Albany NY). 2020; 12(5):4558-4572. PMC: 7093190. DOI: 10.18632/aging.102911. View

Xuan J, Sun W, Lin P, Zhou K, Liu S, Zheng L . RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res. 2017; 46(D1):D327-D334. PMC: 5753293. DOI: 10.1093/nar/gkx934. View

Takayama K, Misawa A, Suzuki T, Takagi K, Hayashizaki Y, Fujimura T . TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun. 2015; 6:8219. DOI: 10.1038/ncomms9219. View

10.

Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D . The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017; 551(7679):251-255. DOI: 10.1038/nature24456. View

11.

Yi D, Wang R, Shi X, Xu L, Yilihamu Y, Sang J . METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression. Oncol Rep. 2020; 43(5):1375-1386. PMC: 7107905. DOI: 10.3892/or.2020.7515. View

12.

Dai F, Wu Y, Lu Y, An C, Zheng X, Dai L . Crosstalk between RNA mA Modification and Non-coding RNA Contributes to Cancer Growth and Progression. Mol Ther Nucleic Acids. 2020; 22:62-71. PMC: 7486578. DOI: 10.1016/j.omtn.2020.08.004. View

13.

Feng P, Ding H, Yang H, Chen W, Lin H, Chou K . iRNA-PseColl: Identifying the Occurrence Sites of Different RNA Modifications by Incorporating Collective Effects of Nucleotides into PseKNC. Mol Ther Nucleic Acids. 2017; 7():155-163. PMC: 5415964. DOI: 10.1016/j.omtn.2017.03.006. View

14.

Bourgeois G, Ney M, Gaspar I, Aigueperse C, Schaefer M, Kellner S . Eukaryotic rRNA Modification by Yeast 5-Methylcytosine-Methyltransferases and Human Proliferation-Associated Antigen p120. PLoS One. 2015; 10(7):e0133321. PMC: 4510066. DOI: 10.1371/journal.pone.0133321. View

15.

Squires J, Patel H, Nousch M, Sibbritt T, Humphreys D, Parker B . Widespread occurrence of 5-methylcytosine in human coding and non-coding RNA. Nucleic Acids Res. 2012; 40(11):5023-33. PMC: 3367185. DOI: 10.1093/nar/gks144. View

16.

RajBhandary U, Stuart A, Faulkner R, Chang S, Khorana H . Nucleotide sequence studies on yeast phenylalanine sRNA. Cold Spring Harb Symp Quant Biol. 1966; 31:425-34. DOI: 10.1101/sqb.1966.031.01.055. View

17.

Nombela P, Miguel-Lopez B, Blanco S . The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021; 20(1):18. PMC: 7812662. DOI: 10.1186/s12943-020-01263-w. View

18.

Chen W, Feng P, Tang H, Ding H, Lin H . RAMPred: identifying the N(1)-methyladenosine sites in eukaryotic transcriptomes. Sci Rep. 2016; 6():31080. PMC: 4980636. DOI: 10.1038/srep31080. View

19.

Liu Z, Xiao X, Yu D, Jia J, Qiu W, Chou K . pRNAm-PC: Predicting N(6)-methyladenosine sites in RNA sequences via physical-chemical properties. Anal Biochem. 2016; 497:60-7. DOI: 10.1016/j.ab.2015.12.017. View

20.

Dixit D, Prager B, Gimple R, Poh H, Wang Y, Wu Q . The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2020; 11(2):480-499. PMC: 8110214. DOI: 10.1158/2159-8290.CD-20-0331. View